Literature DB >> 8037194

Cefotetan-induced hemolytic anemia causing severe hypophosphatemia.

S Mohammed1, S Knoll, A van Amburg, P A Mennes.   

Abstract

Phosphorus is a major component of proteins, phospholipids, and nucleotides. The increased uptake of phosphorus by cells during erythropoiesis can result in severe hypophosphatemia. A case of severe hypophosphatemia due to accelerated erythropoiesis in response to Cefotetan-induced hemolytic anemia is described. The hypophosphatemia seen during hemolysis may be the result, rather than the cause, of the hemolysis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8037194     DOI: 10.1002/ajh.2830460422

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  4 in total

Review 1.  Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia.

Authors:  David M Charytan; Steven Fishbane; Jolanta Malyszko; Peter A McCullough; David Goldsmith
Journal:  Am J Kidney Dis       Date:  2015-02-26       Impact factor: 8.860

2.  A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients.

Authors:  Wajeh Y Qunibi; Carlos Martinez; Mark Smith; Joseph Benjamin; Antoinette Mangione; Simon D Roger
Journal:  Nephrol Dial Transplant       Date:  2010-10-07       Impact factor: 5.992

3.  Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study.

Authors:  Merche Prats; Ramon Font; Carmen García; Carmen Cabré; Manel Jariod; Alberto Martinez Vea
Journal:  BMC Nephrol       Date:  2013-07-31       Impact factor: 2.388

4.  Serum inorganic phosphorus levels predict 30-day mortality in patients with community acquired pneumonia.

Authors:  Mohammad E Naffaa; Mona Mustafa; Mohje Azzam; Roni Nasser; Nizar Andria; Zaher S Azzam; Eyal Braun
Journal:  BMC Infect Dis       Date:  2015-08-13       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.